Hill S R, Pollard L A, Bibby M C
Clinical Oncology Unit, University of Bradford, West Yorkshire, U.K.
Anticancer Res. 1992 Nov-Dec;12(6B):2169-75.
Previous in vitro studies with 5-Fluorouracil (5-FU) plus Tauromustine (TCNU) demonstrated sequence-dependent effects. This study extended these investigations into an in vivo experimental model, relevant to clinical disease. A transplantable murine adenocarcinoma of the colon, MAC 29, was shown to have stable histology and reproducible growth. This model was used to determine the influence of sequence of administration of this drug combination. Effects ranged from antagonism, with 5-FU given 24 hours before TCNU, to addition, simultaneous treatment, and synergism, 5-FU 24 hours after TCNU. Careful consideration of sequence should be made during the evaluation of this combination in clinical trials.
先前使用5-氟尿嘧啶（5-FU）加牛磺莫司汀（TCNU）的体外研究表明存在序列依赖性效应。本研究将这些调查扩展到与临床疾病相关的体内实验模型中。一种可移植的小鼠结肠腺癌MAC 29，显示出稳定的组织学和可重复的生长。该模型用于确定这种药物组合给药顺序的影响。效应范围从拮抗作用（5-FU在TCNU前24小时给药）到相加作用、同时治疗以及协同作用（5-FU在TCNU后24小时给药）。在临床试验评估该组合时，应仔细考虑给药顺序。
